Journal of Clinical Epidemiology
Volume 50, Issue 5 , Pages 611-618 , May 1997

Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: Evidence of confounding by exposure characteristics

,Accepted 15 January 1997.

References 

  1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Preventive Med. 1991;20:47–63
  2. In: Consensus Development Conference: Prophylaxis and treatment of osteoporosis. 2nd ed. Am J Med. 90:1991;p. 107–110
  3. Ziel HK. Estrogen's role in endometrial cancer. Obstet Gynecol. 1982;60:509–515
  4. Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev. 1993;15:66–79
  5. Stanford JL, Thomas DB. Exogenous progestins and breast cancer. Epidemiol Rev. 1993;15:98–107
  6. Grady D, Rubin SM, Petitti DB, et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037
  7. Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women's characteristics. J Clin Epidemiol. 1993;46:211–219
  8. Adami HO. Long-term consequences of estrogen and estrogen-progestin replacement. Cancer Causes & Control. 1992;3:83–90
  9. Hemminki E, Sihvo S. A review of postmenopausal hormone therapy recommendations: Potential for selection bias. Obstet Gynecol. 1993;82:1021–1028
  10. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers?. Am J Epidemiol. 1996;143:971–978
  11. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Int Med. 1991;115:455–456
  12. Vandenbroucke JP. Postmenopausal estrogen and cardioprotection (Editorial). Lancet. 1991;337:833–834
  13. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: Is the evidence biased?. Br Med J. 1994;308:1268–1269
  14. Grodstein F. Invited commentary: Can selection bias explain the cardiovascular benefits of estrogen replacement therapy?. Am J Epidemiol. 1996;143:979–982
  15. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38:199–210
  16. Persson I, Adami HO, Johansson EDB, Lindberg BS, Manell P, Westerholm B. A cohort study on estrogen treatment and risk of endometrial cancer: Evaluation of method and its applicability. Eur J Clin Pharmacol. 1983;25:625–632
  17. Persson I, Adami HO, Bergkvist L, et al.  Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. Br Med J. 1989;298:147–151
  18. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 1989;321:293–297
  19. Naessén T, Persson I, Adami HO, et al.  Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Int Med. 1990;113:95–103
  20. Falkeborn M, Persson I, Adami HO, et al.  The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet & Gynaecol. 1992;99:821–828
  21. Bergkvist L, Adami HO, Persson I, Schairer C. Risk factors for breast and endometrial cancer in a cohort of women treated with menopausal estrogen. Int J Epidemiol. 1988;17:732–737
  22. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756–762
  23. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Int Med. 1991;325:756–762
  24. Persson I, Bergkvist L, Adami HO. Reliability of women's histories of climacteric estrogen treatment assessed by prescription forms. Int J Epidemiol. 1987;16:222–228
  25. National Pharmaceutical Company . Swedish Drug Statistics 1978–1992. yearly publication Apoteksbolaget. 1982–1992;

☆ Supported by grants from the National Cancer Institute, USA, and the Swedish Cancer Society.

PII: S0895-4356(97)00004-8

Journal of Clinical Epidemiology
Volume 50, Issue 5 , Pages 611-618 , May 1997

Article Tools